65,437 trials
Chronic Kidney Disease on Hemodialysis · Secondary Hyperparathyroidism
Primary: Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level — 53.3; 41.9; 38.7; 56.7 Percentage of participants
Intragastric Acidity
Primary: Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment — 53.265; 46.933; 17.215 Percentage of Time
Osteoporosis Postmenopausal
Primary: Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of Treatment — 2; 55; 134; 77 participants — p=<0.0001
Cervical Dystonia
Primary: Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score From Baseline — -16.21; 42.48; 25.81; -11.40 points on a scale
Hypertension
Primary: Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks) — -0.69; -0.85; -0.75; -8.97 mm Hg — p=0.0008
Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9. — -16; -9 units on scale
Influenza · Orthomyxoviridae Infections
Primary: Number of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination 1 — 10; 2; 2; 1 Participants
Hepatitis A
Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL
Severe Acne Vulgaris
Primary: Percent Change From Baseline in Total Lesion Counts at Week 12. — -64; -41 % of change
Excessive Daytime Sleepiness · Narcolepsy · Obstructive Sleep Apnea/Hypopnea Syndrome
Primary: Safety and Tolerability in This Patient Population (Narcolepsy, OSAHS, SWSD) Over Time (up to 2 Years) — 667 Participants
Carcinoma, Renal Cell
Primary: Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST) — 13 participants
Atherosclerosis
Primary: Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 — 40.593; 40.422; 41.013; 40.182 percent (absolute change)
Contraception
Primary: Maximum Concentration (Cmax) (Pharmacokinentic Parameter (PK)) for All Subjects in the Pharmacokinetically Evaluable (ASPE) Group — 168; 105; 37.1 pg/ml
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) — -1.790; -1.517 percentage (%) of total haemoglobin
Antibiotics Associated Colitis · Pulmonary Infection
Primary: Presence of AAD — 12 participants — p=<0.05